News - A team of researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain’s natural defense mechanisms in people with Alzheimer’s disease. This major breakthrough, details of which are presented today in an early online edition of the Proceedings of the National Academy of Sciences (PNAS), opens the door to the development of a treatment for Alzheimer’s disease and a vaccine to prevent the illness.
News - Medicago announces that it has been awarded an Indefinite Delivery / Indefinite Quantity contract from the Defense Advanced Research Projects Agency based on Medicago having met all the technical requirement standards for the contract. As a result of Medicago having met these requirements and standards, Medicago is now allowed to bid for the manufacture and delivery of certain tobacco-produced proteins, for which Medicago has already demonstrated a proven ability.
News - Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
News - “Our research identifies a molecular pathway by which morphine can increase pain, and suggests potential new ways to make morphine effective for more patients,” says senior author Dr. Yves De Koninck, Professor at Université Laval in Quebec City. The team included researchers from The Hospital for Sick Children (SickKids) in Toronto, the Institut universitaire en santé mentale de Québec, the US and Italy.
News - CQDM is proud to announce the launch of its third annual Explore competition. The main goal of this program is to support unconventional and highly innovative projects that could lead to the development of cutting edge tools or technologies that have a potential disruptive impact on biopharmaceutical research. This competition is widely open to the Quebec scientific community including private organizations and academic research institutions.
Press releases - Under the auspices of the Capitale‐Nationale ACCORD program (Concerted Action for Regional Development Cooperation), Agnès Maltais, Minister of Labour, Employment and Social Solidarity and Minister Responsible for the Quebec City region, and Régis Labeaume, Mayor of Quebec City, recently announced their financial support for the implementation of a biomanufacturing research platform for vaccines and other medical treatments. At an assessed cost of $670,000, the project will receive $215,000 in funding from the Quebec City Bureau (BCN) and the Quebec Department of Finance and the Economy and $200,000 from the City of Quebec. In addition, the participating companies, Medicago and Folia Biotech, will be investing $255,000 between them.
News - Medicago and Folia Biotech, a private biotechnology firm that focuses on vaccine enhancement using plant virus recombinant protein as an adjuvant, announce the receipt of$415,000 in financial support from the Quebec government and the municipality of Quebec City to fund a feasibility study for a unique biopharmaceutical production project, known as BioProduction21, part of the Quebec Region's Life Science ACCORD Cluster.
News - Aeterna Zentaris announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin Lymphoma, suggesting that this subgroup could represent the target population for future studies.
News - Medicago announced that it has been awarded a non-refundable contribution of up to $493,000 from the National Research Council of Canada Industrial Research Assistance Program. The funding will support the development of new potency assays and process analytical technologies for Medicago's pandemic and seasonal influenza VLP vaccine candidates.
News - Medicago announces that Mr. Mike Wanner, Executive Vice-President Operations, will be presenting at the 5th Annual LD MICRO Growth Conference. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles on December 5 and 6, 2012.